185 related articles for article (PubMed ID: 38697174)
21. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.
Vangala D; Ladigan S; Liffers ST; Noseir S; Maghnouj A; Götze TM; Verdoodt B; Klein-Scory S; Godfrey L; Zowada MK; Huerta M; Edelstein DL; de Villarreal JM; Marqués M; Kumbrink J; Jung A; Schiergens T; Werner J; Heinemann V; Stintzing S; Lindoerfer D; Mansmann U; Pohl M; Teschendorf C; Bernhardt C; Wolters H; Stern J; Usta S; Viebahn R; Admard J; Casadei N; Fröhling S; Ball CR; Siveke JT; Glimm H; Tannapfel A; Schmiegel W; Hahn SA
Genome Med; 2021 Jul; 13(1):116. PubMed ID: 34271981
[TBL] [Abstract][Full Text] [Related]
22. Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All.
Martins M; Mansinho A; Cruz-Duarte R; Martins SL; Costa L
Adv Exp Med Biol; 2018; 1110():113-131. PubMed ID: 30623369
[TBL] [Abstract][Full Text] [Related]
23. Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.
Sartore-Bianchi A; Siena S
Handb Exp Pharmacol; 2018; 249():145-159. PubMed ID: 28382467
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab for treatment of metastatic colorectal cancer.
Cerea G; Ricotta R; Schiavetto I; Maugeri MR; Sartore-Bianchi A; Moroni M; Artale S; Siena S
Ann Oncol; 2006 Jun; 17 Suppl 7():vii66-7. PubMed ID: 16760297
[TBL] [Abstract][Full Text] [Related]
25. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor-targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models.
Miyamoto Y; Muguruma N; Fujimoto S; Okada Y; Kida Y; Nakamura F; Tanaka K; Nakagawa T; Kitamura S; Okamoto K; Miyamoto H; Sato Y; Takayama T
Cancer Sci; 2019 Jun; 110(6):1921-1930. PubMed ID: 30973663
[TBL] [Abstract][Full Text] [Related]
27. STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics.
Zulkifli AA; Tan FH; Putoczki TL; Stylli SS; Luwor RB
Mol Cell Endocrinol; 2017 Aug; 451():15-23. PubMed ID: 28088467
[TBL] [Abstract][Full Text] [Related]
28. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
[TBL] [Abstract][Full Text] [Related]
29. Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
Lièvre A; Ouine B; Canet J; Cartier A; Amar Y; Cacheux W; Mariani O; Guimbaud R; Selves J; Lecomte T; Guyetant S; Bieche I; Berger F; de Koning L
Br J Cancer; 2017 Dec; 117(12):1819-1827. PubMed ID: 29024937
[TBL] [Abstract][Full Text] [Related]
30. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapy for metastatic colorectal cancer.
Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies.
de Mello RA; Marques AM; Araújo A
World J Gastroenterol; 2013 Oct; 19(38):6315-8. PubMed ID: 24151349
[TBL] [Abstract][Full Text] [Related]
33. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
[TBL] [Abstract][Full Text] [Related]
34. The quest to overcome resistance to EGFR-targeted therapies in cancer.
Chong CR; Jänne PA
Nat Med; 2013 Nov; 19(11):1389-400. PubMed ID: 24202392
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer.
Foroughi S; Tie J; Gibbs P; Burgess AW
Growth Factors; 2019 Dec; 37(5-6):209-225. PubMed ID: 31878812
[TBL] [Abstract][Full Text] [Related]
36. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.
Tie J; Desai J
Target Oncol; 2015 Jun; 10(2):179-88. PubMed ID: 25119972
[TBL] [Abstract][Full Text] [Related]
37. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
38. Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.
Caiazza F; Elliott L; Fennelly D; Sheahan K; Doherty GA; Ryan EJ
Biomark Med; 2015; 9(4):363-75. PubMed ID: 25808440
[TBL] [Abstract][Full Text] [Related]
39. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer.
Dienstmann R; De Dosso S; Felip E; Tabernero J
Mol Oncol; 2012 Feb; 6(1):15-26. PubMed ID: 22189054
[TBL] [Abstract][Full Text] [Related]
40. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives.
Martinelli E; Ciardiello D; Martini G; Troiani T; Cardone C; Vitiello PP; Normanno N; Rachiglio AM; Maiello E; Latiano T; De Vita F; Ciardiello F
Ann Oncol; 2020 Jan; 31(1):30-40. PubMed ID: 31912793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]